BioNTech (BNTX) CFO Ramon Zapata Gomez files initial Form 3 ownership

Rhea-AI Filing Summary

BioNTech SE filed an initial beneficial ownership report for Chief Financial Officer Ramon Zapata Gomez on Form 3. This filing formally registers him as an officer subject to insider reporting rules. The available data shows no transactions or derivative positions reported in this Form 3 excerpt.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Zapata Gomez Ramon

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Humza Bokhari, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the BioNTech (BNTX) Form 3 for Ramon Zapata Gomez represent?

The Form 3 for BioNTech’s CFO Ramon Zapata Gomez is an initial statement of beneficial ownership. It registers him as an insider officer, establishing the baseline from which future Form 4 or Form 5 transaction reports will be measured.

Does the BioNTech (BNTX) Form 3 show any stock purchases or sales by the CFO?

The provided Form 3 data for BioNTech’s CFO shows no reported purchases or sales. Transaction counts and share figures are all zero, indicating this filing serves purely as an initial ownership statement without trading activity disclosed in this excerpt.

What insider role does Ramon Zapata Gomez hold at BioNTech (BNTX)?

Ramon Zapata Gomez is identified as the Chief Financial Officer of BioNTech SE. As CFO, he is considered an officer and insider under SEC rules, which requires public reporting of his beneficial ownership and qualifying future transactions in company securities.

Are any derivative securities reported for the BioNTech (BNTX) CFO on this Form 3?

The derivative securities section in the available data for the BioNTech CFO’s Form 3 is empty. This indicates no options, warrants, or other derivative holdings are listed in this specific excerpt of the initial ownership report.

Why is a Form 3 filing for BioNTech (BNTX) important to investors?

A Form 3 filing for BioNTech identifies a new or existing insider, such as the CFO, whose ownership and future trades must be publicly reported. This transparency helps investors track insider positions and later compare them with transactions on Forms 4 and 5.